Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07753720 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv6
  2. Site contact updatedv5
  3. Enrollment reopened
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Start date: Aug 10, 2026 to Aug 13, 2026
    • Site details revised
    v4
  4. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Jul 30, 2026 to Aug 10, 2026
    v3
  5. Study Status, Eligibilityv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized trial will compare daily tadalafil 5 mg as adjunct therapy versus monotherapy in men with on-demand PDE5 inhibitor-resistant erectile dysfunction. The study will evaluate changes in erectile function, treatment satisfaction, partner satisfaction, and safety over 12 weeks.
Trial Details
NCT Number NCT07753720
Lead Sponsor Al-Azhar University
Conditions
(from sponsor)		 Erectile Dysfunction, Tadalafil
Related terms Erectile Dysfunction
Enrollment 260 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov